Abstract | INTRODUCTION: METHODS: RESULTS: CONCLUSIONS: Although previous clinical trials have not demonstrated a survival difference between patients receiving neoadjuvant versus adjuvant chemotherapy for breast cancer, our study suggests an overall survival benefit in patients with pCR following neoadjuvant chemotherapy compared with patients receiving adjuvant therapy. It is clear that a prospective study needs to be carried out to better elucidate the timing of chemotherapy in patients with TNBC.
|
Authors | Carla S Fisher, Cynthia X Ma, William E Gillanders, Rebecca L Aft, Timothy J Eberlein, Feng Gao, Julie A Margenthaler |
Journal | Annals of surgical oncology
(Ann Surg Oncol)
Vol. 19
Issue 1
Pg. 253-8
(Jan 2012)
ISSN: 1534-4681 [Electronic] United States |
PMID | 21725686
(Publication Type: Journal Article)
|
Chemical References |
- Receptors, Estrogen
- Receptors, Progesterone
- Receptor, ErbB-2
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Breast Neoplasms
(drug therapy, mortality, pathology)
- Carcinoma, Ductal, Breast
(drug therapy, mortality, pathology)
- Carcinoma, Lobular
(drug therapy, mortality, pathology)
- Chemotherapy, Adjuvant
- Female
- Follow-Up Studies
- Humans
- Immunoenzyme Techniques
- Middle Aged
- Neoadjuvant Therapy
- Neoplasm Staging
- Prognosis
- Prospective Studies
- Receptor, ErbB-2
(metabolism)
- Receptors, Estrogen
(metabolism)
- Receptors, Progesterone
(metabolism)
- Remission Induction
- Retrospective Studies
- Survival Rate
|